Published in final edited form as:

Biochem Biophys Res Commun. 2007 March 2; 354(1): 33–38.

Cloning, expression and characterization of an alternatively spliced variant of human heparanase

Nicola J. Nasser^{*,†}, Aaron Avivi^{*,‡}, Moran Shushy[†], Israel Vlodavsky^{†,‡}, and Eviatar Nevo^{*}

^{*} *Institute of Evolution, International Graduate Center of Evolution, University of Haifa, Haifa 31905, Israel*

[†] *Cancer and Vascular Biology Research Center, the Bruce Rappaport Faculty of Medicine, Technion, Haifa 31096, Israel*

Abstract

Heparanase is an endoglycosidase that cleaves heparan sulfate in the extracellular matrix (ECM) and hence participates in ECM degradation and remodeling. Heparanase is involved in fundamental biological processes such as cancer metastasis, angiogenesis and inflammation. Alternative splicing in the coding region of human heparanase was not reported. Here, we report the cloning of a splice variant of human heparanase that lacks exon 5 and is missing 174 bp compared to the wild type cDNA. Splice 5 is expressed as a 55 kDa protein compared to the 65 and 50 kDa latent and active wild type enzyme. Splice 5 was not detected in the incubation medium of tumor cells as opposed to the wild type latent heparanase. Splice 5 escaped proteolytic cleavage, was devoid of HS degradation activity and exhibited diffused rather than granular cellular localization.

Heparan sulfate proteoglycans (HSPG) are macromolecules associated with the cell surface and extracellular matrix (ECM) of a wide range of cells [1–3]. The basic HSPG structure consists of a protein core to which several linear heparan sulfate (HS) chains are covalently O-linked. The polysaccharide chains are typically composed of repeating hexuronic and D-glucosamine disaccharide units that are modified at various positions by sulfation, epimerization and N-acetylation, yielding clusters of sulfated disaccharides separated by low or non-sulfated regions [1–3]. Heparan sulfate binds to and assembles ECM proteins, including fibronectin, laminins, and interstitial collagens, and is playing important roles in cell-cell and cell-ECM interactions [1–3].

Mammalian heparanase capable of HS cleavage was cloned by several groups [4–7]. Despite of earlier reports on the existence of several distinct mammalian HS degrading endoglycosidases (heparanases), cloning of the same single gene suggests that mammalian cells express primarily a single dominant functional heparanase enzyme. Recently, we cloned heparanase of the blind subterranean mole rat (*Spalax*) and characterized a related splice variant originating from skipping of exon #7 [8]. Splice 7 was shorter by 48 base pairs compared to the wild type cDNA, with no frame-shift. Despite the fact that splice 7 possesses the same signal peptide as that of the wild type enzyme, it was not detected in the incubation medium, escaped processing and activation and hence was devoid of enzymatic ability [8].

[‡] To whom correspondence should be addressed: Israel Vlodavsky, Ph.D., Tel. +972-4-8295410, Fax. +972-4-8523947, vlodavsk@cc.huji.ac.il. Aaron Avivi, Ph.D., Tel. +972-4-8240446, Fax. +972-4-8246554, aaron@research.haifa.ac.il.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Alternative splicing in the coding region of human heparanase was, to the best of our knowledge, not reported. On average, each human gene generates three alternatively spliced mRNAs [9,10]. This fact and the cloning of splice 7 heparanase of *Spalax*, led us to the search for human splice variants of the heparanase gene. Here, we describe the cloning and characterization of a unique splice variant of human heparanase which results from skipping of exon #5.

Materials and Methods

RNA and cDNA preparation

RNA of human kidney excised from a patient suffering from renal cell carcinoma, was kindly provided by Prof. Shimon Meretyk (Urology Department, Rambam Health Care Campus, Haifa, Israel). cDNA was prepared by reverse transcription (M-MLV reverse transcriptase, Promega, Madison, WI) of 1 µg total RNA, using oligo(dT)₁₅ and random primers [4].

Gene cloning

For cloning splice variants of human heparanase, we performed PCR utilizing the following primer pair designed according to the published human heparanase sequence [4,5]: sense 5'-CCA GAG GCT TGT CTC CTG CGT AC-3', anti-sense 5'-CAT AAA GCC AGC TGC AAA GGT G -3'; cDNA of kidney was used as a template.

DNA sequencing

DNA sequencing was performed using vector-specific and gene-specific primers, with an automated DNA sequencer (ABI Prism™ model 310 Genetic Analyzer, Perkin Elmer, Foster city, CA).

Cells and transfections

Human MCF-7 breast carcinoma and U87 glioma cells were cultured in Dulbecco's modified Eagle's medium (DMEM, 4.5 gr. glucose/liter) containing 10% fetal calf serum (FCS), and antibiotics, as described [11]. Cells were grown in 60 mm tissue culture dishes and transfected with a total of 1–2 µg plasmid DNA mixed with 6 µl of FuGene transfection reagent (Roche Applied Science, Mannheim, Germany) and 94 µl DMEM. Transiently transfected cells were obtained after 24–48 h incubation at 37°C. Stable populations of transfected cells were selected with G418 [4,11].

Western blot analysis

Cells (2×10^6) transfected with either insert free pcDNA3 vector alone, or pcDNA3 containing the wild type human heparanase or its splice variant (splice 5), were lysed in 1ml lysis buffer containing 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% Triton X-100, and a mixture of protease inhibitors (Roche Applied Science, Mannheim, Germany). Heparanase was concentrated by incubating (4°C, 1 h) the cell lysate or the incubation medium with ConA beads (Amersham Biosciences, Uppsala, Sweden) and washing (x2) with PBS [12,13]. The beads were boiled (3 min) in sample buffer, centrifuged and the supernatant subjected to SDS-PAGE and immunoblot analysis, using polyclonal anti-heparanase antibody #1453, as described [12,13]. Antibody # 1453 was raised in rabbit against the entire 65 kDa heparanase precursor [13]. Immunoreactive bands were detected by the enhanced chemiluminescence reagent, as described [4,11–14].

Heparanase activity

Cell lysates prepared from 1×10^6 cells by three cycles of freezing and thawing in heparanase reaction buffer (20 mM phosphate–citrate buffer, pH 6.0, 1 NaCl) were incubated (4 h, 37 °C,

pH 6.0) mM dithiothreitol, 1 mM CaCl₂, and 50 mM with ³⁵S-labeled ECM, prepared as described [4]. The incubation medium containing ³⁵S-labeled HS degradation fragments was analyzed by gel filtration on a Sepharose CL-6B column [4,11]. Fractions (0.2 ml) were eluted with phosphate-buffered saline (PBS) and their radioactivity counted in a β -scintillation counter. Degradation fragments of HS side chains were eluted from Sepharose 6B at 0.5 < K_{av} < 0.8 (peak II, fractions 20–30) [4,11]. Each experiment was performed at least three times and the variation in elution positions (K_{av} values) did not exceed ±15% of the mean.

Immunocytochemistry

U87 glioma cells stably transfected with the wild type heparanase or its splice variant #5 were grown on glass cover-slips for 8 h. Staining was then performed essentially as described [12]. Briefly, cells were fixed with cold methanol for 10 minutes, washed with PBS and subsequently incubated in PBS containing 10% normal goat serum for 1 hour at room temperature, followed by 2 hours incubation with anti-heparanase monoclonal antibody [15] (kindly provided by Dr. Hua-Quan Miao, Imclone Systems Inc, New York, N.Y). Cells were extensively washed with PBS, incubated with secondary antibody (Jackson ImmunoResearch) for 1 hour, washed and mounted in Vectashield (Vector, Burlingame, CA) [12].

Results

Identification and cloning of a splice variant of human heparanase lacking exon 5

We cloned a novel splice variant (#5) of heparanase from the cDNA of human kidney infiltrated by renal cell carcinoma cells. Sequence analysis revealed that it originates from splicing out of exon 5, yielding a deletion of 174 bp compared to the wild type cDNA (Figure 1). The reading frame of the splice variant is conserved compared to that of the wild type gene, and its predicted amino acid sequence is shorter by 58 residues (485 aa for splice #5 compared to 543 aa of the wild type enzyme) (Figure 2). The predicted amino acid sequence of splice 5 heparanase has three potential N-glycosylation sites (Fig. 1), compared to six in the wildtype protein (Figure 2). Gel electrophoresis of PCR products amplified using primers designed around the deletion segment and kidney cDNA as a template, revealed both the wild type and spliced forms. Plasmids containing the coding region of either form were subjected to PCR and used as positive controls (Figure 3A).

Functional expression of wild type and splice 5 human heparanases in mammalian cells

We compared the expression pattern of splice 5 and wild type human heparanases, applying U87 and MCF-7 cells transiently transfected with each form. Western immunoblotting (using anti-heparanase antibody 1453) of cell lysates revealed a single band of about 55 kDa in splice 5 transfected cells compared to 65 and 50 kDa protein bands in cells transfected with the wild type heparanase. In order to evaluate secretion of splice 5, we cultured (24 h, 37°C) U87 and MCF-7 cells transfected with human wild type heparanase, splice 5, or insert free mock plasmid. Western blot analysis of the incubation medium using anti-heparanase antibodies revealed secretion and accumulation of the wild type 65 kDa latent enzyme in the culture medium (Figure 3B). In contrast, splice 5 was not detected in the incubation medium (Figure 3B), indicating its inability to be secreted and to accumulate in the culture medium.

Heparanase enzymatic activity

We assessed the ability of heparanase splice variant #5 to degrade HS in intact ECM. For this purpose, lysates of U87 cells stably transfected with the full length human heparanase, splice 5, or mock control were incubated (4 h, 37 °C, pH 6.0) with intact naturally produced sulfate-labeled ECM. Labeled degradation fragments released into the incubation medium were then analyzed by gel filtration on Sepharose 6B. Incubation of the ECM with lysates of cells

transfected with the wild type human heparanase resulted in release of low-molecular weight labeled degradation fragments eluted toward the V_t of the column (fractions 20–30, $0.5 < K_{av} < 0.8$) (Fig. 3C). These fragments were shown to be degradation products of HS as they were i) 5–6 fold smaller than intact HS side chains; ii) resistant to further digestion with papain and chondroitinase ABC, and iii) susceptible to deamination by nitrous acid [16]. In contrast, both splice 5 and mock transfected cells failed to produce HS degradation products, indicating lack or undetectable levels of heparanase enzymatic activity.

Localization of Human Heparanase and its splice variant in glioma cells

U87 cells stably transfected with the full length human heparanase or its splice variant #5, were immunostained with monoclonal anti-heparanase antibody [15] in order to evaluate the subcellular localization of the wild type enzyme versus its splice variant. As shown in figure 4, wild-type heparanase exhibited predominantly a perinuclear, granular pattern, suggesting lysosomal-endosomal localization, as previously described [17]. In contrast, staining of cells transfected with splice variant #5 yielded a diffused cytoplasmic staining (Figure 4).

Discussion

The unexpected low number of genes identified in the human and mouse genomes [9,10,18] raise the question of how mammalian organisms could be maintained with 25000–35000 genes? Through alternative splicing, the sequence of one gene can yield a variety of RNAs and thus different proteins [9,10,18–27]. On average, each human gene generates three alternatively spliced mRNAs [9,10]. This takes place by several mechanisms including exon skipping, skipping part of an exon, or intron retention [9,24]. Some of the alternatively spliced mRNA's are degraded by nonsense mediated mRNA decay. The distinction of functionally important variants from aberrant splicing remains a challenging issue [27].

The genomic organization of human heparanase and the existence of a splice variant in the untranslated regions of the gene were described by Dong et al [28]. Recently, we cloned the *Spalax* heparanase and identified several splice variants in its coding region, of which splice variant #7 was described [8]. Alternative splicing in the coding region of human heparanase was not reported.

Here, we identified a splice variant in the coding region of human heparanase (skipping exon 5) which maintained the reading frame of the wild type gene. Splice variant #5 lacks 174 base pairs encoding for 58 amino acids, including the active site proton donor (Glu²²⁵). Unlike the wild type enzyme, splice 5 was not detected in the medium of transfected cells, suggesting a defect in its secretion (Fig. 3B). This defect may be due to: i) conformational change that hinders exit of the spliced enzyme out of the cell, ii) lack of an epitope in splice 5 that is critical for heparanase recognition by a potential receptor and/or active transporter, and iii) very efficient reuptake of splice #5 into the cells, leaving undetectable levels of the splice variant in the culture medium.

Whereas the two proteolytic sites described for processing of the wild type heparanase [4,11] are conserved in splice #5, processing of the splice variant (i.e., conversion of pro-enzyme into its active form) could not be detected (Fig. 3B). Recently, cathepsin L was implicated in processing and activation of latent heparanase [29]. It is conceivable that the lack of processing of splice #5 is due to a defect in its interaction with cathepsin L, found in lysosomes [12] and the incubation medium [30,31] of some cells. Lack of proteolytic processing may account for the lack of heparanase enzymatic activity in splice 5 (Fig. 3C). Heparanase is implicated in a variety of non-enzymatic functions (i.e., signal transduction, cell adhesion and survival) [13, 32] which may still be conserved in splice 5. These functions are currently being investigated. Several other splice variants of heparanase were identified, resulting in expression of truncated

forms (our unpublished results) whose biological significance and function remain to be elucidated.

Acknowledgements

We thank Alma Joel for technical assistance. This work was supported by grants from the Israel Science Foundation (grant 549/06); National Cancer Institute, NIH (grant RO1-CA106456); the Israel Cancer Research Fund; and the Rappaport Family Institute Fund.

References

1. Kjellen L, Lindahl U. Proteoglycans: structures and interactions. *Annu Rev Biochem* 1991;60:443–475. [PubMed: 1883201]
2. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M. Functions of cell surface heparan sulfate proteoglycans. *Annu Rev Biochem* 1999;68:729–777. [PubMed: 10872465]
3. Iozzo RV. Matrix proteoglycans: from molecular design to cellular function. *Annu Rev Biochem* 1998;67:609–652. [PubMed: 9759499]
4. Vlodavsky I, Friedmann Y, Elkin M, Aingorn H, Atzmon R, Ishai-Michaeli R, Bitan M, Pappo O, Peretz T, Michal I, Spector L, Pecker I. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. *Nat Med* 1999;5:793–802. [PubMed: 10395325]
5. Hulett MD, Freeman C, Hamdorf BJ, Baker RT, Harris MJ, Parish CR. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. *Nat Med* 1999;5:803–809. [PubMed: 10395326]
6. Kussie PH, Hulmes JD, Ludwig DL, Patel S, Navarro EC, Seddon AP, Giorgio NA, Bohlen P. Cloning and functional expression of a human heparanase gene. *Biochem Biophys Res Commun* 1999;261:183–187. [PubMed: 10405343]
7. Toyoshima M, Nakajima M. Human heparanase. Purification, characterization, cloning, and expression. *J Biol Chem* 1999;274:24153–24160. [PubMed: 10446189]
8. Nasser NJ, Nevo E, Shafat I, Ilan N, Vlodavsky I, Avivi A. Adaptive evolution of heparanase in hypoxia-tolerant *Spalax*: gene cloning and identification of a unique splice variant. *Proc Natl Acad Sci U S A* 2005;102:15161–15166. [PubMed: 16204381]
9. Ast G. How did alternative splicing evolve? *Nat Rev Genet* 2004;5:773–782. [PubMed: 15510168]
10. Ast G. The alternative genome. *Sci Am* 2005;292:40–77. [PubMed: 15915813]
11. Goldshmidt O, Zcharia E, Aingorn H, Guatta-Rangini Z, Atzmon R, Michal I, Pecker I, Mitrani E, Vlodavsky I. Expression pattern and secretion of human and chicken heparanase are determined by their signal peptide sequence. *J Biol Chem* 2001;276:29178–29187. [PubMed: 11387326]
12. Zetser A, Levy-Adam F, Kaplan V, Gingis-Velitski S, Bashenko Y, Schubert S, Flugelman MY, Vlodavsky I, Ilan N. Processing and activation of latent heparanase occurs in lysosomes. *J Cell Sci* 2004;117:2249–2258. [PubMed: 15126626]
13. Zetser A, Bashenko Y, Edovitsky E, Levy-Adam F, Vlodavsky I, Ilan N. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. *Cancer Res* 2006;66:1455–1463. [PubMed: 16452201]
14. Levy-Adam F, Abboud-Jarrous G, Guerrini M, Beccati D, Vlodavsky I, Ilan N. Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase. *J Biol Chem* 2005;280:20457–20466. [PubMed: 15760902]
15. Kelly T, Suva LJ, Huang Y, Macleod V, Miao HQ, Walker RC, Sanderson RD. Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases. *Cancer Res* 2005;65:5778–5784. [PubMed: 15994953]
16. Vlodavsky I, Fuks Z, Bar-Ner M, Ariav Y, Schirmacher V. Lymphoma cell-mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: relationship to tumor cell metastasis. *Cancer Res* 1983;43:2704–2711. [PubMed: 6601984]
17. Goldshmidt O, Nadav L, Aingorn H, Irit C, Feinstein N, Ilan N, Zamir E, Geiger B, Vlodavsky I, Katz BZ. Human heparanase is localized within lysosomes in a stable form. *Exp Cell Res* 2002;281:50–62. [PubMed: 12441129]

18. Brett D, Pospisil H, Valcarcel J, Reich J, Bork P. Alternative splicing and genome complexity. *Nat Genet* 2002;30:29–30. [PubMed: 11743582]
19. Boue S, Letunic I, Bork P. Alternative splicing and evolution. *Bioessays* 2003;25:1031–1034. [PubMed: 14579243]
20. Modrek B, Lee C. A genomic view of alternative splicing. *Nat Genet* 2002;30:13–19. [PubMed: 11753382]
21. Modrek B, Resch A, Grasso C, Lee C. Genome-wide detection of alternative splicing in expressed sequences of human genes. *Nucleic Acids Res* 2001;29:2850–2859. [PubMed: 11433032]
22. Magen A, Ast G. The importance of being divisible by three in alternative splicing. *Nucleic Acids Res* 2005;33:5574–5582. [PubMed: 16192573]
23. Carmel I, Tal S, Vig I, Ast G. Comparative analysis detects dependencies among the 5' splice-site positions. *RNA* 2004;10:828–840. [PubMed: 15100438]
24. Kondrashov FA, Koonin EV. Evolution of alternative splicing: deletions, insertions and origin of functional parts of proteins from intron sequences. *Trends Genet* 2003;19:115–119. [PubMed: 12615001]
25. Pagani F, Baralle FE. Genomic variants in exons and introns: identifying the splicing spoilers. *Nat Rev Genet* 2004;5:389–396. [PubMed: 15168696]
26. Cartegni L, Chew SL, Krainer AR. Listening to silence and understanding nonsense: exonic mutations that affect splicing. *Nat Rev Genet* 2002;3:285–298. [PubMed: 11967553]
27. Baek D, Green P. Sequence conservation, relative isoform frequencies, and nonsense-mediated decay in evolutionarily conserved alternative splicing. *Proc Natl Acad Sci U S A* 2005;102:12813–12818. [PubMed: 16123126]
28. Dong J, Kukula AK, Toyoshima M, Nakajima M. Genomic organization and chromosome localization of the newly identified human heparanase gene. *Gene* 2000;253:171–178. [PubMed: 10940554]
29. Abboud-Jarrous G, Rangini-Guetta Z, Aingorn H, Atzmon R, Elgavish S, Peretz T, Vlodavsky I. Site-directed mutagenesis, proteolytic cleavage, and activation of human proheparanase. *J Biol Chem* 2005;280:13568–13575. [PubMed: 15659389]
30. Hashimoto Y, Kondo C, Kojima T, Nagata H, Moriyama A, Hayakawa T, Katunuma N. Significance of 32-kDa cathepsin L secreted from cancer cells. *Cancer Biother Radiopharm* 2006;21:217–224. [PubMed: 16918298]
31. Klose A, Zigrino P, Denhofer R, Mauch C, Hunzelmann N. Identification and discrimination of extracellularly active cathepsins B and L in high-invasive melanoma cells. *Anal Biochem* 2006;353:57–62. [PubMed: 16620747]
32. Gingis-Velitski S, Zetser A, Flugelman MY, Vlodavsky I, Ilan N. Heparanase induces endothelial cell migration via protein kinase B/Akt activation. *J Biol Chem* 2004;279:23536–23541. [PubMed: 15044433]

1 atgtctgctgcgctcgaagcctgcgctgcgcgcgcgcgctgatgtctgctcctggggccg
1 M L R S K P A L P P P L M L L L G P
 61 ctgggtccctctccctggcgccctgccccgacctgcgcaagcacaggacgtcgtggac
21 L G P L S P G A L P R P A Q A Q D V V D
 121 ctggacttcttcacccaggagccgctgcacctggtgagccctcggtcctgtccgtcacc
41 L D F F T Q E P L H L V S P S F L S V T
 181 attgacgccaacctggccacggaccgcgggttcctcatcctcctgggttctccaaagctt
61 I D A N L A T D P R F L I L L G S P K L
 241 cgtaccttgccagaggcttgctcctgcgtacctgaggtttggtggcaccacagacagac
81 R T L A R G L S P A Y L R F G G T K T D
 301 ttcctaattttcgatccaagaaggaatcaacctttgaagagagaagtactggcaatct
101 F L I F D P K K E S T F E E R S Y W Q S
 361 caagtcaaccaggatatttgcaaatatggatccatccctcctgatgtggaggagaagtta
121 Q V N Q D I C K Y G S I P P D V E E K L
 421 cgggttggaatggccctaccaggagcaattgctactccgagaacactaccagaaaaagttc
141 R L E W P Y Q E Q L L L R E H Y Q K K F
 481 aagaacagcacctactcaaaacctaacagtttccctaagaaggctgatattttcatcaat
161 K N S T Y S K P N S F L K K A D I F I N
 541 gggtcgcagttaggagaagattttatcaattgcataaacttcaagaaagtccaccttc
181 G S Q L G E D F I Q L H K L L R K S T F
 601 aaaaatgcaaaactctatggtcctgatgttggtcagcctcgaagaaagacggctaagatg
201 K N A K L Y G P D V G Q P R R K T A K M
 661 ctgaagagcttctgaaggctgggtggagaagtgattgattcagttacatggcatcactac
221 L K S F L K A G G E V I D S V T W H H Y
 721 tatttgaatggacggactgtaccagggaagattttctaaccctgatgtattggacatt
241 Y L N G R T A T R E D F L N P D V L D I
 781 tttatttcatctgtgcaaaaagttttccaggtggttgagagcaccaggcctggcaagaag
261 F I S S V Q K V F Q V V E S T R P G K K
 841 gtctggttaggagaacaagctctgcatatggaggcggagcgcccttgctatccgacacc
281 V W L G E* T S S A Y G G G A P L L S D T
 901 ttgacagctggctttatgtggctggataaattggcctgtcagccgaatgggaatagaa
301 F A A G F M W L D K L G L S A R M G I E
 961 gtggtgatgaggcaagtattctttggagcaggaaactaccatttagtgatgaaaacttc
321 V V M R Q V F F G A G N Y H L V D E N F
 1021 gatcctttacctgattattggctatctcttctgttcaagaaattggtgggcaccaaggtg
341 D P L P D Y W L S L L F K K L V G T K V
 1081 ttaattggcaagcgtgcaaggttcaagagaaggaagcttcgagtataccttcattgaca
361 L M A S V Q G S K R R K L R V Y L H C T
 1141 aacactgacaatccaaggtataaagaaggagatttaactctgtatgccataaacctccat
381 N T D N P R Y K E G D L T L Y A I N L H
 1201 aacgtcaccaagtaacttgcggttacctatcctttttctaacaagcaagtggataaatac
401 N V T K Y L R L P Y P F S N K Q V D K Y
 1261 cttctaagacctttgggacctcatggattactttccaaatctgtccaactcaatggtcta
421 L L R P L G P H G L L S K S V Q L N G L
 1321 actctaagatggtggatgatcaaaccttgccaccttaatggaaaaacctctccggcca
441 T L K M V D D Q T L P P L M E K P L R P
 1381 ggaagttcactgggcttgccagctttctcatatagttttttgtgataagaaatgccaaa
461 G S S L G L P A F S Y S F F V I R N A K
 1441 gttgctgcttgcatctga
481 V A A C I *

Figure 1.

Nucleotide and predicted amino acid sequences of splice 5 human heparanase. Nucleotide sequences are shown above the predicted amino acid sequences. Numbers on the left correspond to nucleotides (Roman) and amino acid residues (bold italic). The signal peptide is underlined. The catalytic nucleophile Glu residue is in bold with asterisks above. The three potential N-glycosylation sites are shaded.

S5	1	MLLRSKPALPPPLMLLLGPLGPLSPGALPRPAQAQDVVDLDFFTQEPLH	50
WT	1	MLLRSKPALPPPLMLLLGPLGPLSPGALPRPAQAQDVVDLDFFTQEPLH	50
S5	51	LVSPSFLSVTIDANLATDPRFLILLGSPKLRTLARGLSPAYLRFGGTKTD	100
WT	51	LVSPSFLSVTIDANLATDPRFLILLGSPKLRTLARGLSPAYLRFGGTKTD	100
S5	101	FLIFDPKKESTFEERSYWQSQVNQDICKYGSIPPDVEEKLRLWPYQEQL	150
WT	101	FLIFDPKKESTFEERSYWQSQVNQDICKYGSIPPDVEEKLRLWPYQEQL	150
S5	151	LLREHYQKKFK N STYSK.....	167
WT	151	LLREHYQKKFK N STYSRSSVDVLYTFANCSGLDLIFGLNALLRTADLQWN	200
S5	168	PNSFLKKADIFINGSQLGEDFIQLH	192
WT	201	SSNAQLLLDYCSSKGY N ISWELG N EPNSFLKKADIFINGSQLGEDFIQLH	250
S5	193	KLLRKSTFKNAKLYGPDVGQPRRKTA K MLKSFLKAGGEVIDSVTWHHYL	242
WT	251	KLLRKSTFKNAKLYGPDVGQPRRKTA K MLKSFLKAGGEVIDSVTWHHYL	300
S5	243	NGRTATREDFLNPDVLDIFISSVQKV F QVVESTRPGKKVWL G ETSSAYGG	292
WT	301	NGRTATREDFLNPDVLDIFISSVQKV F QVVESTRPGKKVWL G ETSSAYGG	350
S5	293	GAPLLSDTFAAGFMWLDKLGLSARMGIEVVMRQVFFGAGNYHLVDENFDP	342
WT	351	GAPLLSDTFAAGFMWLDKLGLSARMGIEVVMRQVFFGAGNYHLVDENFDP	400
S5	343	LPDYWLSLLFKKLVGTKVLMASVQGSKRRKLRVYLHCTNTDNPRYKEGDL	392
WT	401	LPDYWLSLLFKKLVGTKVLMASVQGSKRRKLRVYLHCTNTDNPRYKEGDL	450
S5	393	TLYAINLH N VTKYLRPLPYPF S SNKQVDKYLLRPLGPHGLLSKSVQLNGLTL	442
WT	451	TLYAINLH N VTKYLRPLPYPF S SNKQVDKYLLRPLGPHGLLSKSVQLNGLTL	500
S5	443	KMVDDQTLPLMEKPLRPGSSSLGLPAFSYSFFVIRNAKVAACI*	486
WT	501	KMVDDQTLPLMEKPLRPGSSSLGLPAFSYSFFVIRNAKVAACI*	544

Figure 2.

Comparison of splice 5 (S5) and wild-type (WT) human heparanase amino acid sequences (GCG alignment program). The two catalytic Glu residues, the proton donor and nucleophile, are marked in bold. Note that the proton donor is missing in splice 5. Potential N-glycosylation sites are shaded. Note that splice 5 lacks three out of the six N-glycosylation sites found in the wild type protein.

Figure 3.

Cloning and expression of human heparanase splice variant lacking exon 5. **A.** Semi-quantitative RT-PCR using primers located around the human heparanase cDNA region encoded by exon 5. Bands of 579 bp represent the wild type enzyme, while those of 405 bp represent its spliced 5 form. Lane 1: Reaction mixture alone; Lane 2: cDNA of kidney; Lanes 3 and 4: Plasmids containing the cDNA sequence corresponding to the wild type and the splice 5 human heparanases, respectively. Left to the DNA ladder (lane 0) are the respective numbers of base pairs. **B.** Western blot analysis utilizing anti-heparanase antibody 1453 on lysates and culture media of U87 and MCF-7 cells transfected with either a mock empty vector (lane 1), or vectors containing the human wild type (lane 2) or splice 5 (lane 3) heparanases. **C.** Heparanase enzymatic activity. Lysates of U87 cells stably transfected with pcDNA3 vectors containing splice 5 (▲) or wild type (▪) heparanases vs. mock, insert free plasmid alone (◆), were incubated (4 h, 37 °C, pH 6.0) with ^{35}S -labeled ECM. Labeled degradation fragments released into the incubation medium were analyzed by gel filtration on Sepharose 6B. Labeled material (fractions 20–30), representing HS degradation products, was obtained only in cells transfected with the wild type enzyme (▪).

Figure 4.

Localization of Human Heparanase and its splice variant in glioma cells. U87 cells stably transfected with the full length wild type (WT) human heparanase or its splice variant #5 (S5), were immunostained with monoclonal anti-heparanase antibody. Note that staining for wild-type heparanase is predominantly of perinuclear, granular pattern, while splice variant #5 exhibits a diffused cytoplasmic staining.